EMA, WHO, and FDA standards
At Oriberg, we believe that access to life-saving healthcare solutions begins with regional production capabilities. Our Bio Investment vertical supports governments, investors, and manufacturers in emerging markets to build vaccine and biologics manufacturing self-reliance—often within a three-year roadmap.
End-to-end infrastructures
Vaccine production (including bulk substance and fill-finish)
In-vitro diagnostic kits (IVDs) Monoclonal antibodies and advanced biologics
Our network spans Africa, the Middle East, South Asia, and Asia-Pacific, enabling rapid knowledge transfer, financing, and equipment delivery. We provide support across:
- Feasibility studies and regulatory alignment (WHO, EMA, US FDA)
- Financing for facility development and equipment procurement
- Supply chain integration and sustainability planning
By investing in bio-manufacturing independence, we help bridge the healthcare gap—transforming underserved markets into hubs of pharmaceutical innovation and resilience.
Want to Explore Bio Investment Opportunities?
Get in touch with our specialist team to discuss how Oriberg can support your government, company, or fund in advancing healthcare sovereignty and global pharma equity.
Years working experience.
1M+
Finance and trading projects
4K
Where are we stronger
bio investment financing, biotech financing solutions, vaccine R&D funding, biologics manufacturing finance, biotech infrastructure support, life sciences finance, global bio manufacturing, biopharma investment UAE, Oriberg bio investment, fill-finish vaccine facilities, life sciences trade finance, biologics development support, bio manufacturing turnkey, pharma financing UAE, biotech sector credit line, vaccine supply chain support, bio research equipment leasing, financial solutions for biopharma